Scimago Lab
powered by Scopus
Formerly the IP & Science
business of Thomson Reuters


eISSN: 1643-3750

Leonurine Attenuates Hyperalgesia in Mice with Induced Adenomyosis

Jichan Nie, Xishi Liu

(Shanghai Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China (mainland))

Med Sci Monit 2017; 23:1701-1706

DOI: 10.12659/MSM.900233

Published: 2017-04-08

BACKGROUND: Adenomyosis, defined as the invasion of endometrial glands and stroma into the myometrium, is a common gynecological disorder. In the present study we report on the effect of leonurine on ICR mice with adenomyosis induced by neonatal tamoxifen.
MATERIAL AND METHODS: After being treated with tamoxifen for 4, 8, and 12 weeks, we assessed body weight and pain modulation in mice in hotplate tests. The mice were divided into 5 groups: a low-dose leonurine treatment group, a high-dose leonurine treatment group, a valproic acid (VPA) treatment group, a vehicle only treatment group, and a blank control group. We evaluated body weight, pain modulation in hotplate tests, and the depth of myometrial infiltration. Immunoreactivity staining of progesterone receptor (PR), nuclear factor-κB phosphorylated-p65 (p-p65), cyclooxygenase-2 (COX-2), and oxytocin receptor (OTR) was evaluated by immunohistochemistry.
RESULTS: The measurement of the body weight, myometrial infiltration, and pain modulation showed that neonatal tamoxifen treatment led to adenomyosis. Leonurine treatment appeared to decrease hyperalgesia and myometrial infiltration. Immunoreactivity staining showed decreased p-p65, COX-2, and OTR protein expressions.
CONCLUSIONS: Our results indicate that leonurine attenuates hyperalgesia in mice with induced adenomyosis via down-regulating expressions of p-P65, COX-2, and OTR, and could be beneficial for treating adenomyosis.

Keywords: adenomyosis, Hyperalgesia, Leonurus